Kyle Rickner
Family Medicine · Yukon, OKNPI 1023020641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,164 and has fallen 86.7% since, to $154 in 2025.
Across 224 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$433
- AbbVie$423
- Novo Nordisk$382
- AstraZeneca$257
- Amgen$208
- Johnson & Johnson$207
- plus $2K from 30 others
Across 2,656 payments — averaging $5533.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5.9M
- Modernatx, Inc.$5.8M
- Pfizer$945K
- Bavarian Nordic A/s$570K
- GSK$322K
- Boehringer Ingelheim$263K
- plus $921K from 15 others
What the payments were for
- Food & beverage$3,640100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $433 |
| AbbVie(2 entities) | 25 | $423 |
| Novo Nordisk | 21 | $382 |
| AstraZeneca | 16 | $257 |
| Amgen | 13 | $208 |
| Johnson & Johnson | 13 | $207 |
| Otsuka America Pharmaceutical, Inc. | 15 | $206 |
| Merck | 12 | $191 |
| Eisai Inc. | 6 | $147 |
| Boehringer Ingelheim | 8 | $142 |
| Lilly USA, LLC | 7 | $110 |
| Therapeuticsmd, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $93 |
| Bayer | 3 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $65 |
| GSK | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $57 |
| Abbott | 3 | $48 |
| Biogen | 2 | $47 |
| Corcept Therapeutics | 3 | $44 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Genentech USA, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Nevro Corp. | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $11 |
How this compares
$3,640 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $39,723 |
| MounjaroTirzepatide | 13 | $13,885 |
| EliquisApixaban | 15 | $12,515 |
| TrulicityDulaglutide | 13 | $12,232 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 39 | $11,780 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,572 |
| VascepaIcosapent Ethyl | 11 | $5,239 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $4,693 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,515 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 14 | $870 |
| Quetiapine Fumarate | 31 | $431 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $413 |
| Levothyroxine Sodium | 42 | $369 |
| Pantoprazole Sodium | 26 | $351 |
| Pregabalin | 14 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $142 | $39,72357 claims |
| Lilly USA, LLCMounjaro, Trulicity | $110 | $26,11626 claims |
| PfizerEliquis, Abrysvo | $433 | $24,29554 claims |
| GSKTrelegy Ellipta, Shingrix | $61 | $12,26535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Yukon
- Marion StudebakerYukon$13K
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.